难治性肺炎支原体肺炎患儿免疫功能变化及匹多莫德免疫干预作用研究

Study on Immune Function and Effect of Pidotimod Intervention in Children with Refractory Mycoplasma Pneumoniae Pneumonia

目的:探讨难治性肺炎支原体肺炎(RMPP)患儿免疫功能变化及匹多莫德的干预作用。方法:50例RMPP患儿及50例健康儿童纳入本研究,将RMPP患儿随机分为A、B两组,A组患儿予常规阿奇霉素联合匹多莫德治疗,B组患儿常规阿奇霉素治疗,检测对照组儿童及RMPP患儿治疗前后外周血T细胞亚群的变化,并比较A、B两组患儿的临床疗效。结果:RMPP患儿与对照组比较,血清CD3+、CD4+、CD4+/CD8+明显降低,差异有统计学意义(P<0.05);治疗后,A、B两组RMPP患儿血清CD3+、CD4+及CD4+/CD8+比值较治疗前明显升高,且A组明显高于B组水平,差异均有统计学意义(P<0.05);随访期间A组患儿平均病情反复次数、持续时间及使用抗生素时间均明显少于B组,差异均有统计学意义(P<0.05)。结论:难治性肺炎支原体肺炎患儿存在免疫功能紊乱,匹多莫德可通过调节免疫平衡,增强患儿免疫力,进而提高临床疗效。

Objective：To investigate the change of immune function and effect of immune intervention in children with refractory mycoplasma pneumoniae pneumonia （ RMPP ） .Method：50 children with RMPP and 50 cases of healthy children were studied ,and RMPP children were randomly divided into groups A , B, group A were treated with conventional azithromycin , group B were combined with pidotimod , the peripheral blood T cell subsets were etected in control and RMPP children （before and after treatment）,and clinical ef-ficacy were compared. Result： The level of serum CD3＋ ,CD4＋ and CD4＋/CD8＋ in RMPP children was sig- nificantly lower than the control group（ P〈0.05 ） ; after treatment, the level of serum CD3＋ , CD4＋ and CD4＋/ CD8＋ in group A and B was significantly higher than before treatment, and those in group A was significantly higher than group B, the differences were statistically significant （P〈0.05） ; the average number of iterations illness, duration and time of use of antibiotics in group A were significantly less than group B （P〈0.05）. Conclusion： There＇s immune dysfunction in children with RMPP, pidotimod can regulate the immune bal- ance, strengthen the immune system in children, and to improve clinical efficacy.